Cover Image
Read Now

New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control

Marking the 200th National Meeting of the American Chemical Society, The Division of Nuclear Chemistry and Technology hosted a group of about 90 scientists from 15 different countries to discuss the new trends in radiopharmaceutical synthesis, quality assurance and regulatory control. This event too...

Full description

Bibliographic Details
Other Authors: Emran, Ali M. (Editor)
Format: eBook
Language:English
Published: New York, NY Springer US 1991, 1991
Edition:1st ed. 1991
Subjects:
Nuclear Medicine
Chemistry, Organic
Pharmacology
Organic Chemistry
Ultrasonics
Online Access:
Collection: Springer Book Archives -2004 - Collection details see MPG.ReNa
Table of Contents:
  • 1.1 Introductory Remarks
  • 1.2 Overview
  • 1.3 A Muscarinic Receptor Ligand: Review of the Chemistry and Applications
  • 2.1 Aspects on the Synthesis and Design of 11C-Tracers for PET
  • 2.2 Special Problems Associated with the Synthesis of High Specific Activity Carbon-11 Labeled Radiotracers
  • 2.3 PET Radiopharmaceuticals via Reductive Carboxylation
  • 2.4 [13N] Labeled Tracers, Synthesis and Applications
  • 2.5 Cu1+ Assisted Nucleophilic Exchange Radiohalogenation: Application and Mechanistic Approach
  • 2.6 Potential Breast Tumor Imaging Agents: Fluorotamoxifen and Derivatives
  • 2.7 Fluorinated Azabicycloesters as Muscarinic Receptor Ligands for Application with PET
  • 2.8 Flourine-18 Ligands for the In Vivo Study of ?-Adrenergic Receptors in the Heart and Lung
  • 2.9 Design and Radiofluorination of Benzamide Dopamine D2 Receptor Ligands
  • 3.1 A Synthetic Porphyrin with High Affinity for Lung Cancer Cells and Inflamed Lymphatic Tissue
  • 7.4 Regulation of Cyclotron Radiopharmaceutical Production and Distribution: An Agreement State Perspective
  • 7.5 New Drug Approval Process for Radiopharmaceuticals
  • 7.6 Abbreviated New Drug Applications (ANDAS): Future Trends in Radiopharmaceuticals
  • 6.2 Quality Assurance Considerations Related to “In-House” Radiopharmaceutical Preparations Utilizing Positron Emitting Radionuclides
  • 6.3 The Role of High Performance Liquid Chromatography In Radiochemical/Radiopharmaceutical Synthesis and Quality Assurance
  • 6.4 Experience from a National Quality Assurance System on Radiopharmaceuticals
  • 6.5 Radiopharmaceutical Production for PET: Quality Assurance Practice, Experience and Issues
  • 6.6 Post-Column Reactor Determination of Aluminum Concentration in Cyclotron Produced Radiorubidium
  • 6.7 Implications of the Food, Drug and Cosmetic Act on the Quality Assurance of Radiopharmaceuticals used in the United States
  • 6.8 Quality Assurance in Radiochemical/Radiopharmaceutical Manufacturing
  • 7.1 Regulatory Control ofRadiopharmaceutics
  • 7.2 Regulatory Control of Radiopharmaceuticals
  • 7.3 Development of European Regulations on Radiopharmaceuticals
  • 4.3 The Synthesis of Halogenated Radiopharmaceuticals using Organomercurials
  • 4.4 Synthesis of Radiopharmaceuticals Via Organoboranes
  • 4.5 Radiosotope Incorporation via Aryl and Alkenyl Trialkyltin Intermediates
  • 5.1 Robots In the Radiopharmaceutical Laboratory: Will They Replace the Chemist?
  • 5.2 The Use of Transducers for Automated Radiopharmaceutical Synthesis Procedures
  • 5.3 Facilitating the Design and Operation of Computer-Controlled Radiochemistry Synthesizers with an “Electronic Toolbox”
  • 5.4 Knowledge-Based Automated Radiopharmaceutical Manufacturing for Positron Emission Tomography
  • 5.5 Robotic Thin Layer Chromatography Instrument for Synthetic Chemistry
  • 5.6 Automated Radiochemical Processing for Clinical PET
  • 5.7 Captive Solvent Methods for Fast, Simple, Carbon-11 Radioalkylation
  • 6.1 Identity, Strength, Purity, Quality and Safety: Common Goals for New Drugs
  • 3.2 Galium and Copper Radiopharmaceutical Chemistry
  • 3.3 Radiometallating Antibodies and Autoantigenic Peptides
  • 3.4 Biomedical Use of Arsenic Radioisotopes
  • 3.5 Improved Extraction Efficiency of Gallium-67 After Irradiation of Zinc-68 with Protons
  • 3.6 Chemistry and Concept for An Automated 72Se/72As Generator
  • 3.7 Radiochemistry of Monoclonal Antibody Labeling
  • 3.8 The Study on the Formulation of A Tc(V)-99m-DMS Lyophilized Instant Kit for Tumor Scintigraphy
  • 3.9 A National Biomedical Tracer Facility
  • 3.10 Tantalum-178-Labeled Radiopharmaceutical Synthesis Via The Intermediate Tantalum Pentachloride — A Potential Myocardial Perfusion Agent
  • 3.11 Status of Lead and Bismuth for Radioimmunoimaging and Therapy
  • 4.1 Use of Organolithium and Organomagnesium Reagents In Radiopharmaceutical Synthesis
  • 4.2 Application of OrganosiliconChemistry to the Synthesis of Gamma and Positron Emitting Radiotracers for Use In Nuclear Imaging Studies

Similar Items